The possible mechanisms of Cilostazol include activating the AMPK-ACC1/SCD1 and AMPK-PGC1α-G6P/PEPCK pathways, regulating the structure and abundance of intestinal flora, SCFAs, and the intestinal barrier function, and finally achieving the effect of treating nonalcoholic fatty liver disease. Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.